WGS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
114.4M
+11.9%
102.3M
-15.5%
121.0M
+3.6%
116.7M
+13.7%
102.7M
Cost of Revenue
36.2M
+6.3%
34.0M
-7.3%
36.7M
+14.0%
32.2M
+1.3%
31.8M
Gross Profit
78.2M
+14.7%
68.2M
-19.1%
84.3M
-0.3%
84.5M
+19.2%
70.9M
Operating Expenses
95.7M
-23.9%
125.7M
+27.6%
98.5M
+12.2%
87.8M
+41.7%
61.9M
R&D
19.7M
-0.7%
19.8M
-19.3%
24.5M
+23.8%
19.8M
+31.5%
15.1M
SG&A
76.0M
+1.9%
74.6M
+0.9%
74.0M
+8.8%
67.9M
+45.0%
46.9M
Operating Income
-17455000
+69.6%
-57471000
-303.7%
-14235000
-337.9%
-3251000
-136.3%
9.0M
EBITDA
-10741000
+44.6%
-19375000
-163.5%
-7354000
-328.2%
3.2M
-78.7%
15.2M
Net Income
-17740000
+72.0%
-63316000
-258.4%
-17666000
-131.4%
-7635000
-170.6%
10.8M
EPS (Basic)
$-0.60
+72.2%
$-2.16
-254.1%
$-0.61
-125.9%
$-0.27
-171.1%
$0.38
EPS (Diluted)
$-0.60
+72.2%
$-2.16
-242.9%
$-0.63
-133.3%
$-0.27
-175.0%
$0.36
Shares (Diluted)
29.7M
+1.3%
29.3M
+5.3%
27.9M
-3.2%
28.8M
-3.2%
29.8M
GeneDx (WGS) โ€” Financials